龙头股单季度业绩降幅收窄，CRO板块能否迎来拐点？

新华财经11-06

新华财经北京11月6日电 6日早盘，CRO板块内个股延续近日上涨态势。至6日午间收盘时，药明康德、康龙化成、凯莱英、昭衍新药等行业龙头股连续三个交易日上涨。从近期披露的2024年三季度报告来看，相关企业第三季度业绩降幅收窄。药明康德2024年第三季度营收同比下降1.96%，第二季度营收降幅为6.55%；第三季度净利润降幅为17.02%，第二季度净利润降幅为26.94%。康龙化成2024年第三季度...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481616826?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-06 11:50","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2481616826","market":"hk","top_or_hot":-1,"title":"龙头股单季度业绩降幅收窄，CRO板块能否迎来拐点？","media":"新华财经","content":"<div>\n<p>新华财经北京11月6日电 6日早盘，CRO板块内个股延续近日上涨态势。至6日午间收盘时，药明康德、康龙化成、凯莱英、昭衍新药等行业龙头股连续三个交易日上涨。从近期披露的2024年三季度报告来看，相关企业第三季度业绩降幅收窄。药明康德2024年第三季度营收同比下降1.96%，第二季度营收降幅为6.55%；第三季度净利润降幅为17.02%，第二季度净利润降幅为26.94%。康龙化成2024年第三季度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106115005a21a93e0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>龙头股单季度业绩降幅收窄，CRO板块能否迎来拐点？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n龙头股单季度业绩降幅收窄，CRO板块能否迎来拐点？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 11:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106115005a21a93e0&s=b><strong>新华财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新华财经北京11月6日电 6日早盘，CRO板块内个股延续近日上涨态势。至6日午间收盘时，药明康德、康龙化成、凯莱英、昭衍新药等行业龙头股连续三个交易日上涨。从近期披露的2024年三季度报告来看，相关企业第三季度业绩降幅收窄。药明康德2024年第三季度营收同比下降1.96%，第二季度营收降幅为6.55%；第三季度净利润降幅为17.02%，第二季度净利润降幅为26.94%。康龙化成2024年第三季度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106115005a21a93e0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106115005a21a93e0&s=b","article_id":"2481616826","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106115005a21a93e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481616826","pubTimestamp":1730865004,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"至6日午间收盘时，药明康德、康龙化成、凯莱英、昭衍新药等行业龙头股连续三个交易日上涨。从近期披露的2024年三季度报告来看，相关企业第三季度业绩降幅收窄。药明康德2024年第三季度营收同比下降1.96%，第二季度营收降幅为6.55%；第三季度净利润降幅为17.02%，第二季度净利润降幅为26.94%。从在手订单和执行情况来看，第四季度新兴业务将重新恢复增长态势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","02359":"药明康德","LU0052750758.USD":"富兰克林中国基金A Acc","BK1191":"制药","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","03759":"康龙化成","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","06821":"凯莱英","BK1583":"高瓴概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD"},"translate_title":"The single-quarter performance decline of leading stocks has narrowed. Can the CRO sector usher in an inflection point?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9,"02359":0.9,"03759":0.9,"06821":0.79},"content_text":"新华财经北京11月6日电 6日早盘，CRO板块内个股延续近日上涨态势。至6日午间收盘时，药明康德、康龙化成、凯莱英、昭衍新药等行业龙头股连续三个交易日上涨。从近期披露的2024年三季度报告来看，相关企业第三季度业绩降幅收窄。药明康德2024年第三季度营收同比下降1.96%，第二季度营收降幅为6.55%；第三季度净利润降幅为17.02%，第二季度净利润降幅为26.94%。康龙化成2024年第三季度营收同比增长10.02%，第二季度营收同比增长0.60%；第三季度扣非后净利润同比下降3.43%，第二季度扣非后净利润同比下降31.64%。凯莱英2024年第三季度营收同比下降18.09%，第二季度营收降幅为45.31%；第三季度净利润降幅为59.68%，第二季度净利润降幅为79.44%。综合近日券商研报，药明康德“订单保持高增长”、“整体业务呈逐步恢复态势”被多家券商分析师提及。例如，中泰证券分析师祝嘉琦和崔少煜认为，预计药明康德2024年有望实现收入端剔除新冠商业化项目后2.7%-8.6%的稳健增长，经调整Non-IFRS归母净利率有望同2023年相当的水平。国信证券分析师彭思宇和张佳博表示，药明康德2024年前三季度美国客户收入增速转正，欧洲客户收入增长提速，在手订单增长趋势良好，维持其“优于大市”评级。康龙化成也获分析师认为“新签订单快速回暖”、“环比业绩进一步改善”。开源证券分析师余汝意表示，康龙化成第三季度归母净利润环比下降，主要系第二季度投资收益较高；2024年前三季度公司新签订单同比增长超18%，连续三个季度实现温和复苏。看好公司长期发展，维持原盈利预测，维持“买入”评级。国海证券分析师万鹏辉称，2024年前三季度凯莱英新兴业务毛利率19.97%，同比下降12.99个百分点，主要受国内市场持续低迷、部分业务仍处于产能爬坡期等因素影响，随着项目交付持续增加，特别是海外项目的增多，这一问题会逐渐得到缓解。从在手订单和执行情况来看，第四季度新兴业务将重新恢复增长态势。编辑：王媛媛","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481616826"}